Virtanen K A, Rouru J, Hänninen V, Savontaus E, Rouvari T, Teirmaa T, Koulu M, Huupponen R
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
Eur J Pharmacol. 1997 Aug 6;332(2):215-8. doi: 10.1016/s0014-2999(97)01104-7.
The effects of a beta 3-adrenoceptor agonist on insulin-induced changes in lipid metabolism were studied in obese male Zucker (fa/fa) rats during euglycaemic clamp. Rats were treated with BRL 35135 (R*, R*-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)-ethyl-amino]-propyl] phenoxyacetate hydrobromide) (0.5 mg/kg per day in drinking water) for three weeks before an euglycaemic hyperinsulinaemic clamp was performed. Insulin infusion lowered serum non-esterified fatty acids and plasma glycerol more efficiently in BRL 35135-treated than in control rats although plasma insulin remained significantly lower in the BRL 35135-treated than in the control rats during the clamp. In conclusion, chronic treatment with BRL 35135 potentiates the effect of insulin on lipid metabolism.
